SINOVAC BIOTECH LTD
SINOVAC BIOTECH LTD (SVA): 12 pipeline candidates · 8 upcoming catalysts · ~38 mo cash runway · 13 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
38.0 months
D/E 0.48 · 0% dilution
Lead: Phase 3
12 candidates
8 upcoming, next in ~136d
N/A
A transparent, data-derived signal for SINOVAC BIOTECH LTDacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$644.7M
Cash
$1.2B
Quarterly Burn
$512.2M
Runway
38.0 mo
Revenue
$386.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| 1wipv+2sipv | Phase 4 |
| 2wipv+1sipv | Phase 4 |
| 3sipv | Phase 4 |
| 3wipv | Phase 4 |
| ev71 inactivated enterovirus vaccine )(for ages 6-71 months） | Phase 3 |
| experimental vaccine | Phase 3 |
| high-dose rsv mrna vaccine | Phase 1/Phase 2 |
| high-dose tetravalent inactivated enterovirus vaccine ) | Phase 3 |
| low-dose of tetravalent inactivated enterovirus vaccine | Phase 3 |
| low-dose rsv mrna vaccine | Phase 1/Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (8)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Frequently asked questions
How many drug candidates are in SINOVAC BIOTECH LTD's pipeline?
SINOVAC BIOTECH LTD (SVA) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SINOVAC BIOTECH LTD's lead drug candidate?
SINOVAC BIOTECH LTD's most advanced tracked candidate is 1wipv+2sipv (Phase 4) for Poliomyelitis.
What is SINOVAC BIOTECH LTD's next catalyst?
SINOVAC BIOTECH LTD's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicit" — expected November 1, 2026.
What is SINOVAC BIOTECH LTD's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SINOVAC BIOTECH LTD has approximately 38.0 months of cash runway.
What is SINOVAC BIOTECH LTD's market capitalization?
SINOVAC BIOTECH LTD's market capitalization is approximately $644.7M.
Get the full picture on SINOVAC BIOTECH LTD
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.